EUVIMEDObjevte EUVIMED
Studienprotokoll

Novel hybrid virtual screening protocol based on pharmacophore and molecular docking for discovery of GSK ‐3β inhibitors

Xiaochang Liu, Jiaxue Yu, Yongyan Luo, Haojian Dong

Chemical Biology & Drug Design · 2023-02 · 101 (2) · 326-339

DOI: 10.1111/cbdd.14111 ↗

At a glance

Studienprotokoll in Chemical Biology & Drug Design, published online on 2022-12-05. Written by Xiaochang Liu and 3 co-authors. Institution: Department of Pharmacy, Guangdong Provincial People's Hospital Zhuhai Hospital (Zhuhai Golden Bay Center Hospital), Zhuhai, China. Major MEDLINE topics: Pharmacophore, Protein Kinase Inhibitors. Cited 4 times so far (Crossref); 22 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

GSK‐3β is a member of the GSKs subfamily and plays a major role in the regulation of transcriptional elongation, which has attracted widespread attention as a therapeutic target for AD. In this study, by combining pharmacophore‐based virtual screening and kinase inhibition assays, we have successfully identified four small molecules that inhibit GSK‐3β activity at micromolar potency. These hit compounds showed drug‐like properties according to Lipinski's rule of five and ADMET. An inter‐complex interaction study showed that all hit compounds adapted well to the ATP pocket of the GSK‐3β protein. Among them, hits 2 and 4 displayed considerable inhibitory activities with IC 50 value of 0.74 ± 0.04 μM and 2.32 ± 0.84 μM respectively. Overall, the discovered GSK‐3β inhibitors act as new chemical leads to develop improved inhibitors that block the interaction of GSK‐3β, and the hybrid virtual screening strategy designed in this study provides an important reference for design and synthesis novel selective GSK‐3β inhibitors.

Subjects

MeSH terms (MEDLINE)

PharmacophoreProtein Kinase InhibitorsMolecular Docking SimulationGlycogen Synthase Kinase 3 betaProtein Binding

Author keywords

GSK-3βhits 2 and 4kinase inhibitionpharmacophore-based virtual screening

Substances

Glycogen Synthase Kinase 3 betaProtein Kinase Inhibitors

Authors and institutions

  • Department of Pharmacy, Guangdong Provincial People's Hospital Zhuhai Hospital (Zhuhai Golden Bay Center Hospital), Zhuhai, China.
  • Department of Cardiology, Vascular Center, Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Coronary, Guangzhou, China.
  • Heart Disease Prevention, Guangdong Provincial People's Hospital, Guangzhou, China.
  • Guangdong Academy of Medical Sciences, Guangzhou, China.

Cite

APA

Liu, X., Yu, J., Luo, Y., & Dong, H. (2023). Novel hybrid virtual screening protocol based on pharmacophore and molecular docking for discovery of GSK ‐3β inhibitors. Chemical Biology & Drug Design, 101(2), 326-339. https://doi.org/10.1111/cbdd.14111

Vancouver

Liu X, Yu J, Luo Y, Dong H. Novel hybrid virtual screening protocol based on pharmacophore and molecular docking for discovery of GSK ‐3β inhibitors. Chemical Biology & Drug Design. 2023;101(2):326-339. doi:10.1111/cbdd.14111

BibTeX
@article{Liu2023,
  author = {Liu, Xiaochang and Yu, Jiaxue and Luo, Yongyan and Dong, Haojian},
  title = {Novel hybrid virtual screening protocol based on pharmacophore and molecular docking for discovery of GSK ‐3β inhibitors},
  journal = {Chemical Biology & Drug Design},
  year = {2023},
  volume = {101},
  number = {2},
  pages = {326--339},
  doi = {10.1111/cbdd.14111}
}
Start for free →